Year: 2014
Type: article
Abstract: BACKGROUND: Diabetic retinopathy (DR) is one of the leading causes of blindness in the United States and world-wide. DR is a silent disease that may go unnoticed until it is too late for effective treatment. Therefore, early detection could improve the chances of therapeutic interventions that would alleviate its effects. METHODOLOGY: Graded fundus photography and systemic data from 3443 ACCORD-Eye Study participants were used to estimate Random Forest (RF) and logistic regression classifiers. We studied the impact of sample size on classifier performance and the possibility of using RF generated class conditional probabilities as metrics describing DR risk. RF measures of variable importance are used to detect factors that affect classification performance. PRINCIPAL FINDINGS: Both types of data were informative when discriminating participants with or without DR. RF based models produced much higher classification accuracy than those based on logistic regression. Combining both types of data did not increase accuracy but did increase statistical discrimination of healthy participants who subsequently did or did not have DR events during four years of follow-up. RF variable importance criteria revealed that microaneurysms counts in both eyes seemed to play the most important role in discrimination among the graded fundus variables, while the number of medicines and diabetes duration were the most relevant among the systemic variables. CONCLUSIONS AND SIGNIFICANCE: We have introduced RF methods to DR classification analyses based on fundus photography data. In addition, we propose an approach to DR risk assessment based on metrics derived from graded fundus photography and systemic data. Our results suggest that RF methods could be a valuable tool to diagnose DR diagnosis and evaluate its progression.
Source: PLoS ONE
Language: English
Topic: Retinal Imaging and Analysis
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funders: Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Sanofi, Omron Healthcare, Bayer HealthCare, Novo Nordisk, National Institutes of Health, Centers for Disease Control and Prevention, National Institute on Aging, National Heart, Lung, and Blood Institute, National Eye Institute, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS, ACCORD, ACCORD, G1955785366, G2121141810, G2150788371, G217652925, ACCORD, G2535401525, G2556935141, ACCORD, G2717754883, G3186661918, G3534128112, G3667269547, G3792726805, G401067667, ACCORD, G4931486092, G552090665, G604937562, G6535417321, G6920961921, G7683729920, G77894727, G781655334, G8499292716, PREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS
OpenAlex ID: W1991669891
